Phio Pharmaceuticals (PHIO) Fundamental Analysis: Revenue, Earnings & Valuation

1.62 / 10

Underperform

Fundamental rating is Underperform with a 1.6/10 score. Inventory turnover and interest coverage are modest positives, but operating revenue growth is flat and liabilities equal total liabilities, indicating weak financial health and high risk.

Analysis Checks(5/7)

Total operating revenue (YoY growth rate %)

Value93.89

Score2/3

Weight-1.47%

1M Return0.13%

Inventory turnover ratio

Value7.59

Score2/3

Weight12.18%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score1/3

Weight17.04%

1M Return-1.69%

Long-term debt to working capital ratio (%)

Value8.82

Score2/3

Weight3.78%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value-59.12

Score2/3

Weight12.38%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value86.87

Score0/3

Weight44.39%

1M Return-4.63%

Cost of sales ratio (%)

Value79.78

Score2/3

Weight11.70%

1M Return-1.13%

Is PHIO fundamentally strong?

PHIO scores 1.62/10 on fundamentals and holds a Premium valuation at present. Backed by its -69.95% ROE, 0.00% net margin, -1.71 P/E ratio, 0.74 P/B ratio, and 84.03% earnings growth, these metrics solidify its Underperform investment rating.